Hypofractionated radiation for stage III lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial studies a radiation treatment schedule called “hypofractionated radiotherapy” for people with locally advanced (stage III) non-small cell lung cancer who cannot have surgery. It aims to see whether this radiation approach works well and is tolerable for your cancer stage.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 70 years old.
- Your overall health/activity level is ECOG 0 or 1 (able to do most daily activities).
- Your lung cancer is non-small cell lung cancer (for example, squamous cell or adenocarcinoma).
- Your cancer is stage III (not stage I–II or IV) confirmed by scans such as CT/PET-CT and brain imaging (cranial MRI).
- You cannot have surgery (the cancer can’t be removed or you choose not to).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests combining immunotherapy with a shorter course of chemoradiation for locally advanced non-small cell lung cancer that hasn't spread. It aims to see if this approach is more effective and tolerable than standard treatment.
This study tests a new combination of radiation therapy, an immunotherapy drug called tislelizumab, and chemotherapy for people with bulky stage III non-small cell lung cancer. The goal is to see if this approach can shrink tumors more effectively and improve outcomes.
This trial tests whether a special type of focused radiation therapy can effectively treat advanced non-small cell lung cancer (the most common type) as an upfront treatment. It may help patients avoid or delay chemotherapy while controlling their cancer.
This trial tests a combination of radiation therapy before surgery, followed by the immunotherapy drug tislelizumab and the targeted therapy drug anlotinib after surgery, for people with stage II to IIIA non-small cell lung cancer (NSCLC). The goal is to see if this approach can improve outcomes for patients whose tumors can be removed surgically.
This trial tests a combination of low-dose radiation, focused high-dose radiation (SBRT), chemotherapy, and an immunotherapy drug (tislelizumab) for people with stage IIA to IIIB non-small cell lung cancer that hasn't been treated yet. The goal is to see if this approach can help shrink tumors and improve outcomes before or instead of surgery.
This study tests using a shorter course of radiation (hypofractionated radiotherapy) combined with immunotherapy for people with limited-stage small-cell lung cancer. The goal is to see if this approach works better at controlling the cancer and may cause fewer side effects.
Hear when a new Toxicity Due to Radiotherapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.